Patent intelligence · US
US 12213964
Isoxazoline parasiticide formulations
Isoxazoline parasiticide formulations
Patent details — US 12213964
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 4, 2025
- Expiration
- Jan 30, 2045
- Applicant
- Tarsus Pharmaceuticals, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/42, A61K31/422, A61K47/26
Quick answer
US 12213964 (Isoxazoline parasiticide formulations) is held by Tarsus Pharmaceuticals, Inc.. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tarsus Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/42, A61K31/422, A61K47/26, A61K9/0048, A61K9/08
More from Tarsus Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364685
Isoxazoline parasiticide formulations
granted -
US 12257263
Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
granted -
US 12171750
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted -
US 11752137
Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
granted -
US 11690826
Methods for treating demodex blepharitis using lotilaner formulations
granted -
US 11690827
Methods for treating ocular Demodex using lotilaner formulations
granted -
US 11197847
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted
Frequently asked questions
What is US patent 12213964?
US 12213964 (Isoxazoline parasiticide formulations) is held by Tarsus Pharmaceuticals, Inc.. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12213964?
Tarsus Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 12213964 expire?
Our index shows an expiration date of Jan 30, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.